Benjamin Hohl sold $25k of ELVN
CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc.. 1,000 shares at an average of $25.04, traded Jan 3, 2025, filed Jan 7, 2025.
Score components
- +22RoleCFO
- +5Trade size$25k at market
- 0Share of holdings soldSold 7.1% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-001007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 13, 2024 | MOption exercise Common Stock10b5-1 | +13,000 | $2.48 | $32k | 13,000 | Jan 7, 2025 |
| Jan 3, 2025 | MOption exercise Common Stock10b5-1 | +1,000 | $2.48 | $2,480 | 14,000 | Jan 7, 2025 |
| Jan 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1,000 | $25.04 | $25k | 13,000 | Jan 7, 2025 |
| Dec 13, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -13,000 | $0.00 | $0 | 155,556 | Jan 7, 2025 |
| Jan 3, 2025 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,000 | $0.00 | $0 | 150,306 | Jan 7, 2025 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | Enliven Therapeutics, Inc. | J. Scott Garland director | $607k 13,000 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $252k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $303k 6,018 shares | -14% | |
| 15Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $69k 3,250 shares | -12% | |
| 2Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $23k 1,000 shares | -4% | |
| 23Weak | Enliven Therapeutics, Inc. | Joseph P Lyssikatos CHIEF SCIENTIFIC OFFICER | $258k 12,500 shares | -1% | |
| 33Weak | Enliven Therapeutics, Inc. | Samuel Kintz PRESIDENT AND CEO | $260k 12,500 shares | -1% | |
| 26Weak | Enliven Therapeutics, Inc. | Anish Patel CHIEF OPERATING OFFICER | $143k 6,667 shares | -2% | |
| 8Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $66k 3,250 shares | -20% | |
| 19Weak | Enliven Therapeutics, Inc. | Anish Patel CHIEF OPERATING OFFICER | $146k 6,667 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.